Takemasa Tsuji to Immunotherapy
This is a "connection" page, showing publications Takemasa Tsuji has written about Immunotherapy.
Connection Strength
0.418
-
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer. Oncoimmunology. 2022; 11(1):2020983.
Score: 0.142
-
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156.
Score: 0.119
-
Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin Cancer Res. 2012 Oct 01; 18(19):5449-59.
Score: 0.074
-
The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004 Sep; 95(9):697-703.
Score: 0.043
-
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8):e104099.
Score: 0.021
-
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44.
Score: 0.020